A phase 1b/2a, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, immunogenicity and efficacy in preventing Vulvovaginal Candidiasis in subjects with recurrent Vulvovaginal Candidiasis following administration of a single dose of ndv-3a vaccine, ndv-3 vaccine, or placebo” (the "protocol").
Qualified Participants Must:
Be 18-50 years of age
Have a current episode of Yeast
Have responded to 3 doses oral fluconazole
Have normal pap smear and be in good health
Qualified Participants May Receive:
Fluconazole and a vaccine injection against Vaginal Candida Albicans and a $100 stipend for each visit to compensate for time and travel.